Evidence-based software for disease management to drive the digital therapeutics market

Digital therapeutics are part of digital health that deliver therapeutic interventions directly to patients through evidence-based, clinically evaluated software for disease management. Digital health collectively refers to all platforms and technologies that provide digital solutions to improve healthcare delivery. Digital health technology includes telehealth, mobile health, smart devices, wearable devices, sensor, and so on.

According to the research report, the global digital therapeutics market size was valued at USD 2.18 Billion in 2020 and is expected to reach USD 13.51 Billion By 2028, growing at a CAGR of 26.1% during the forecast period.

Request Sample Copy of Research Report: https://bit.ly/3e6QR8u

(The sample of this report is readily available on request. The report sample contains a brief introduction to the research report, a Table of Contents, a Graphical introduction of regional analysis, Top players in the market with their revenue analysis, and our research methodology.)

Benefits of Digital Therapeutics

·???????Digital therapeutics offer enhanced and long-lasting health outcomes by applying scientifically developed technologies that monitor all aspects of treatment progression and changes in patient behavior. These technical applications encourage patients to follow prescribed treatment regimes, diets, and exercise routines.

·???????Mobile applications that come under digital therapeutics can improve patients' adherence to treatment by reminding them about the dosage of medicines and the time of intake. In addition, mobile applications deliver sensory stimuli to patients to substitute medications.

Challenges in Large-Scale Adoption of Digital Therapeutics

·???????Clinical Validation: Companies verify efficacy in treating a condition by comparing clinical results to three different metrics. They may compare their product to no treatment, to a minimum standard of care, or a gold standard of treatment. Clinical validation is essential, but the hype regarding these companies can often overshadow the company's actual value.

·???????Regulatory Approval: With the advent of a therapeutic-focused software precertification approval program, DTx is encountering a new FDA approval pathway where pharma has little experience, and DTx companies must make their way.

Browse detailed report with in-depth TOC: https://bit.ly/3wR2aYV

How Digital Therapeutics Products Improve Patient Care

DTx products may expand access to proven therapies, offer treatment options for undertreated conditions, and empower patients with self-management tools. They are used independently or in concert with medications, devices, or other medicines to optimize patient care and health problems.

Additionally, actual world outcomes generated by digital therapeutics may be used to optimize results at individual patient and population levels. DTx products provide clinicians with meaningful, actionable clinical reports at the personal patient level. At a population level, data generated by DTx products may be aggregated to track progress or compare aggregate outcomes based upon the patient's disease state, acuity level, geographic location, age, gender, and so on.?

Key Players

Market participants such as Proteus Digital Health, Inc., Fitbit, Inc., Pear Therapeutics, Inc., Kaia Health, Happify, Inc., Medtronic Plc., Omada Health, Inc., Livongo Health, Inc., Voluntis, Inc., Resmed, Inc., and Welldoc, Inc. are some of the companies operating in the digital therapeutics market.